Shots:

• Ligand to receive $10M up front, ~ $67.5M for development & regulatory milestone, ~ $60M in commercial milestone, ~$120M in sales-related milestones & is eligible to receive royalties on sales of the product which is commercialized by GSK
• The agreement is based on an initial 2020 agreement which will use Icagen’s ion-channel-based discovery technology and expertise in small molecule therapeutics targeting transmembrane proteins to identify genetically-validated targets for ND
• GSK gets an exclusive option to license any identified molecules & will lead the development & commercialization of any drug candidates. Ligand will lead the preclinical activities up to lead optimization

Ref: Businesswire | Image: BioSpace